STOCK TITAN
  1. Home
  2. News
  3. TBPH

Theravance Biopharma, Inc. - TBPH STOCK NEWS

Welcome to our dedicated page for Theravance Biopharma news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Biopharma stock.

Theravance Biopharma, Inc. (NASDAQ: TBPH) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. The company's mission is to pioneer a new generation of small-molecule drugs that better meet patient needs by maximizing efficacy while limiting systemic side effects.

Theravance Biopharma has a strong focus on inflammation and immunology and aims to deliver Medicines that Make a Difference® in people's lives. The company's research expertise has led to the development of the FDA-approved YUPELRI® (revefenacin) inhalation solution, the first once-daily, nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Theravance Biopharma co-promotes YUPELRI with Viatris Inc. under a profit and loss sharing arrangement.

Another promising product in Theravance Biopharma's pipeline is ampreloxetine, a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This drug has the potential to be a first-in-class therapy, addressing a significant unmet medical need for MSA patients.

The company is also involved in strategic collaborations with other pharmaceutical companies to expand its reach and enhance its product pipeline. Their current projects and partnerships are aimed at furthering the development and commercialization of innovative therapies.

Financially, Theravance Biopharma has shown consistent performance, with significant growth in YUPELRI net sales and robust clinical trial activity. Recent achievements include positive results from a Phase III clinical trial of YUPELRI in China and ongoing enrollment in the Phase 3 CYPRESS study for ampreloxetine. These milestones underscore the company's commitment to delivering impactful therapies and driving shareholder value.

Theravance Biopharma continues to leverage its organ-selective drug development expertise to create value and improve patient outcomes. For more information, please visit www.theravance.com.

News

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) to host a virtual KOL event discussing treatment landscape for MSA patients with symptomatic nOH. The event will focus on the clinical development program for ampreloxetine, a potential first-in-class therapy for nOH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
conferences
-
News

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) reported strong financial and operational results for Q4 2023 and full-year 2023. YUPELRI net sales increased by 9% to $60.6 million in Q4, with a full-year revenue of $221 million. The company achieved Non-GAAP profitability in Q4 despite a GAAP net loss of $8.5 million. Additionally, a capital return program reduced shares outstanding by 37%. Ampreloxetine investor event is planned for Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.98%
Tags
earnings
-
News

Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) to participate in CNS Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference. Senior management to host one-on-one meetings. Webcast available on Theravance.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
News

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) will release its Q4 and full year 2023 financial results on Feb 26, 2024, followed by a conference call and webcast. Investors can join the call via phone or web to get updates on the company's performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences earnings
-
News

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Rhea-AI Summary
Theravance Biopharma, ticker symbol TBPH, announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The study compared YUPELRI to Spiriva HandiHaler in adults with severe to very severe COPD and suboptimal peak inspiratory flow rate (PIFR). While the primary endpoint was not met, YUPELRI demonstrated similar lung function improvement and safety profile consistent with previous clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.98%
Tags
none
-
News

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) appoints Jeremy Grant to its Board of Directors, enters into a cooperation agreement with Irenic Capital, and reaffirms its commitment to maximizing shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
management
News

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference

Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) will have its management team, including CEO Rick E Winningham and CFO Aziz Sawaf, holding investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference from January 8-11, 2024, in San Francisco, CA. Investors can request a one-on-one meeting with the management team by contacting investor.relations@theravance.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
News

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) announced a new anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) at the 34th International Symposium on The Autonomic Nervous System. The analysis underscores the clinical relevance of the Orthostatic Hypotension Symptom Assessment domain of the Orthostatic Hypotension Questionnaire, supporting its use as a primary endpoint in clinical studies. Key observations from the analysis include the identification of clinically meaningful thresholds for improvement and worsening of the OHSA composite score, as well as the demonstration of a 1.6 point benefit of ampreloxetine relative to placebo in MSA patients during the randomized withdrawal period of Study 170.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
-
News

Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) to participate in Fireside Chat at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
News

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) and Theravance Biopharma, Inc. (NASDAQ: TBPH) announce positive Phase III results for YUPELRI in China, demonstrating efficacy and safety for COPD patients. The study shows a statistically significant increase in trough FEV1 compared to placebo, supporting a regulatory filing in China in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
clinical trial

FAQ

What is the current stock price of Theravance Biopharma (TBPH)?

The current stock price of Theravance Biopharma (TBPH) is $9.49 as of November 18, 2024.

What is the market cap of Theravance Biopharma (TBPH)?

The market cap of Theravance Biopharma (TBPH) is approximately 473.3M.

What is Theravance Biopharma's primary focus?

Theravance Biopharma focuses on the discovery, development, and commercialization of organ-selective medicines, primarily in the areas of inflammation and immunology.

What is YUPELRI?

YUPELRI (revefenacin) is an FDA-approved, once-daily, nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

What is ampreloxetine?

Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).

Who are Theravance Biopharma’s strategic partners?

Theravance Biopharma collaborates with Viatris Inc. and other pharmaceutical companies to develop and commercialize its products.

What recent achievements has Theravance Biopharma made?

Recent achievements include positive results from a Phase III trial of YUPELRI in China and ongoing enrollment in the Phase 3 CYPRESS study for ampreloxetine.

Where can I find more information about Theravance Biopharma’s products?

More information can be found on Theravance Biopharma’s website at www.theravance.com.

What is the purpose of the CYPRESS study?

The CYPRESS study is a Phase 3 clinical trial to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH.

How does Theravance Biopharma create shareholder value?

Theravance Biopharma creates shareholder value by developing effective, organ-selective medicines and leveraging strategic collaborations to expand its product pipeline.

What is Theravance Biopharma’s mission?

Theravance Biopharma's mission is to pioneer a new generation of small-molecule drugs designed to better meet patient needs by maximizing efficacy and limiting systemic side effects.

How can I listen to Theravance Biopharma's conference calls?

You can listen to conference calls live via the internet on Theravance Biopharma’s website under the Investors section, Presentations and Events.

Stock TBPH logo
Theravance Biopharma, Inc.

Nasdaq:TBPH

TBPH Rankings

#3141 Ranked by Market Cap
N/A Ranked by Dividends

TBPH Stock Data

473.32M
49.17M
5.96%
94.3%
10.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
GEORGE TOWN, GRAND CAYMAN